HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (20) Citing Articles via Google Scholar Google Scholar Articles by Verkman, A. S. Search for Related Content PubMed PubMed Citation Articles by Verkman, A. S.

INVITED REVIEW

Drug discovery in academia

Departments of Medicine and Physiology, Cardiovascular Research Institute, University of California, San Francisco, California 94143-0521

Drug discovery and development is generally done in the commercial rather than the academic realm. Drug discovery involves target discovery and validation, lead identification by high-throughput screening, and lead optimization by medicinal chemistry. Follow-up preclinical evaluation includes analysis in animal models of compound efficacy and pharmacology (ADME: administration, distribution, metabolism, elimination) and studies of toxicology, specificity, and drug interactions. Notwithstanding the high-cost, labor-intensive, and non-hypothesis-driven aspects of drug discovery, the academic setting has a unique and expanding niche in this important area of investigation. For example, academic drug discovery can focus on targets of limited commercial value, such as third-world and rare diseases, and on the development of research reagents such as high-affinity inhibitors for pharmacological "gene knockout" in animal models ("chemical genetics"). This review describes the practical aspects of the preclinical drug discovery process for academic investigators. The discovery of small molecule inhibitors and activators of the cystic fibrosis transmembrane conductance regulator is presented as an example of an academic drug discovery program that has yielded new compounds for physiology research and clinical development.

high-throughput screening; drug development; pharmacology; fluorescence; cystic fibrosis transmembrane conductance regulator

This article has been cited by other articles:

				R. De La Fuente, W. Namkung, A. Mills, and A. S. Verkman Small-Molecule Screen Identifies Inhibitors of a Human Intestinal Calcium-Activated Chloride Channel Mol. Pharmacol., March 1, 2008; 73(3): 758 - 768. [Abstract] [Full Text] [PDF]

				S. M. Rowe, S. Miller, and E. J. Sorscher Cystic Fibrosis N. Engl. J. Med., May 12, 2005; 352(19): 1992 - 2001. [Full Text] [PDF]

				J. Davies and A. Bush Primum Non Nocere: Does the Current Research Publication System (or the Lay Press) Harm Our Patients? Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 937 - 938. [Full Text] [PDF]